+Compare
OVID
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
251.35M

OVID Ovid Therapeutics Forecast, Technical & Fundamental Analysis

Provides medicines to children and adults with neurological disorders

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for OVID with price predictions
08:00 PM EDT Oct 01, 2023

OVID saw its Stochastic Oscillator peaks and leaves the overbought zone

The Stochastic Oscillator for OVID moved out of overbought territory on October 02, 2023. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 50 similar instances where the indicator exited the overbought zone. In of the 50 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 28, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on OVID as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for OVID turned negative on October 02, 2023. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at .

OVID moved below its 50-day moving average on October 02, 2023 date and that indicates a change from an upward trend to a downward trend.

Bullish Trend Analysis

The 10-day moving average for OVID crossed bullishly above the 50-day moving average on September 15, 2023. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where OVID advanced for three days, in of 271 cases, the price rose further within the following month. The odds of a continued upward trend are .

OVID may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. OVID’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.271) is normal, around the industry mean (22.679). P/E Ratio (1.244) is within average values for comparable stocks, (131.550). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.091). Dividend Yield (0.000) settles around the average of (0.033) among similar stocks. P/S Ratio (1250.000) is also within normal values, averaging (308.078).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OVID’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Sorrento Therapeutics, Inc. (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.18B. The market cap for tickers in the group ranges from 402 to 403.32B. NVO holds the highest valuation in this group at 403.32B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -1%. For the same Industry, the average monthly price growth was 18%, and the average quarterly price growth was 23%. SLNO experienced the highest price growth at 494%, while RNAZ experienced the biggest fall at -82%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -29%. For the same stocks of the Industry, the average monthly volume growth was 73% and the average quarterly volume growth was 28%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 87
Price Growth Rating: 69
SMR Rating: 93
Profit Risk Rating: 95
Seasonality Score: -2 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I. Advisor
published Earnings

OVID is expected to report earnings to rise 4.72% to -18 cents per share on November 09

Ovid Therapeutics OVID Stock Earnings Reports
Q3'23
Est.
$-0.19
Q2'23
Beat
by $0.02
Q1'23
Missed
by $0.02
Q4'22
Beat
by $0.01
Q3'22
Beat
by $0.04
The last earnings report on August 04 showed earnings per share of -18 cents, beating the estimate of -20 cents. With 53.93K shares outstanding, the current market capitalization sits at 251.35M.
A.I. Advisor
published General Information

General Information

Provides medicines to children and adults with neurological disorders

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
441 Ninth Avenue
Phone
+1 646 661-7661
Employees
44
Web
https://www.ovidrx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ONERX28.450.09
+0.32%
One Rock
NRARX38.770.04
+0.10%
Neuberger Berman Sustainable Equity R3
TGIWX14.470.01
+0.07%
TIAA-CREF Growth & Income W
RYCTX161.77-0.03
-0.02%
Rydex S&P 500 2x Strategy C
QRSAX33.21-0.22
-0.66%
FPA Queens Road Small Cap Value Advisor

OVID and

Correlation & Price change

A.I.dvisor indicates that over the last year, OVID has been loosely correlated with VKTX. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if OVID jumps, then VKTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OVID
1D Price
Change %
OVID100%
-6.77%
VKTX - OVID
34%
Loosely correlated
-1.63%
AXON - OVID
30%
Poorly correlated
-1.43%
SRNEQ - OVID
30%
Poorly correlated
+1.06%
ALEC - OVID
29%
Poorly correlated
-4.17%
CRIS - OVID
29%
Poorly correlated
-21.09%
More

Groups containing OVID

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OVID
1D Price
Change %
OVID100%
-6.77%
pharmaceuticals
(undefined stocks)
25%
Poorly correlated
-1.16%
neurological
(undefined stocks)
10%
Poorly correlated
-1.80%